|
SG2014012207A
|
|
Compositions and methods for inducing apoptosis
|
|
WO2012018856A2
|
|
Hiv vaccine therapy with concomitant antiviral monotherapy
|
|
WO2011146885A2
|
|
Compositions and methods for lentiviral expression of apoa-1 or variants thereof using spliceosome mediated rna trans-splicing
|
|
EP2326711A2
|
|
Compositions and methods for generation of pluripotent stem cells
|
|
US2011207226A1
|
|
Non-integrating lenti/adeno-associated virus hybrid vector system
|
|
EP2271754A1
|
|
Lentivirus-based immunogenic vectors
|
|
JP2009000120A
|
|
Method and composition for use in spliceosome-mediated rna trans-splicing
|
|
AU2008201651A1
|
|
Methods and compositions for identifying gene function
|
|
AU2008201303A1
|
|
Regulated nucleic acid expression system
|
|
CA2612355A1
|
|
Antibody complexes
|
|
CN101238218A
|
|
Transduction of primary cells
|
|
JP2006345852A
|
|
Antibody conjugate
|
|
EP1797184A2
|
|
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
|
US2006172381A1
|
|
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
|
AU2005326784A1
|
|
Use of RNA trans-splicing for antibody gene transfer and antibody polypeptide production
|
|
WO2006007539A1
|
|
Vector packaging cell line
|
|
US2006194317A1
|
|
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
|
AU2005207053A1
|
|
Expression of ApoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
|
|
EP1677832A1
|
|
Lentivirus vector-based approaches for generating an immune response to hiv humans
|
|
EP1624899A2
|
|
INCREASED TRANSDUCTION USING ABC TRANSPORTER SUBSTRATES that are INHIBITORS
|
